Antimüllerian hormone levels are lower in BRCA2 mutation carriers

BRCA2 mutation carriers have antimullerian hormone (AMH) levels that are significantly lower than healthy low-risk control women and have increased odds of having low AMH levels.

Like Comment

Volume 107, Issue 5, Pages 1256–1265.e6

Authors:

Lauren Johnson, M.D., M.S.C.E, Mary D. Sammel, Sc.D., Susan Domchek, M.D., Allison Schanne, B.A., Maureen Prewitt, B.S.N., Clarisa Gracia, M.D., M.S.C.E.

Abstract:

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

1 Comments

Go to the profile of Dr Elena Kontogianni
Dr Elena Kontogianni over 3 years ago

Should we conceded oocyte freezing to BRCA2 carriers? Is their fertility in general lower than brca2 non-carriers?